公开(公告)号：US11008287B2

公开(公告)日：2021-05-18

申请号：US16341538

申请日：2017-10-13

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Jan Scicinski

IPC: C07D205/04

Abstract: The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoimmune disease, infection, or cancer in a patient. Exemplary sulfoxyalkyl organonitro compounds described herein include ((2-(3,3-dinitroaze-tidin-1-yl)-2-oxoethyl)sulfinyl)-D-alanine and variants thereof.

公开(公告)号：US10906957B2

公开(公告)日：2021-02-02

申请号：US15717199

申请日：2017-09-27

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/71 ,  C12N7/00 ,  A61P35/00 ,  C07K16/00 ,  C12N15/86 ,  A61K48/00 ,  A61K35/768 ,  A61K38/00

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20190352616A1

公开(公告)日：2019-11-21

申请号：US16482055

申请日：2018-01-30

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Christopher Larson

IPC: C12N7/00 ,  A61K35/761 ,  C07K14/705 ,  A61P35/00

Abstract: The invention provides a recombinant adenovirus comprising two (or more) therapeutic transgenes, e.g., CD80 and CD137L. The transgenes are preferably inserted into an E1b-19K insertion site and/or an E3 insertion site.

公开(公告)号：US20160199346A1

公开(公告)日：2016-07-14

申请号：US14965062

申请日：2015-12-10

Applicant: EpicentRx, Inc. ,  Orbital ATK, Inc.

Inventor： MARK D. BEDNARSKI ,  Susan Knox ,  Louis Cannizzo ,  Kirstin Warner ,  Robert Wardle ,  Stephen Velarde ,  Shoucheng Ning

IPC: A61K31/397 ,  A61N5/10 ,  A61K9/00

CPC classification number: A61K31/397 ,  A61K9/0019 ,  A61N5/10 ,  C07D205/04

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

公开(公告)号：US12295976B2

公开(公告)日：2025-05-13

申请号：US17042822

申请日：2019-03-28

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Bryan T. Oronsky ,  Tony R. Reid

IPC: A61K35/761 ,  A61K38/16 ,  C12N15/10 ,  C12N15/861

Abstract: The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.

公开(公告)号：US12109348B2

公开(公告)日：2024-10-08

申请号：US17119423

申请日：2020-12-11

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Scott Caroen

IPC: A61M1/36 ,  A61M1/38

CPC classification number: A61M1/3673 ,  A61M1/36225 ,  A61M1/362266 ,  A61M1/38 ,  A61M2202/0007 ,  A61M2202/0216 ,  A61M2202/0275 ,  A61M2202/0427 ,  A61M2202/0429 ,  A61M2202/0439 ,  A61M2205/75

Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

公开(公告)号：US12054530B2

公开(公告)日：2024-08-06

申请号：US17150993

申请日：2021-01-15

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/71 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86

CPC classification number: C07K14/71 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/30 ,  C12N2710/10332 ,  C12N2710/10333 ,  C12N2710/10343 ,  C12N2710/10371

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US12048793B2

公开(公告)日：2024-07-30

申请号：US17251552

申请日：2019-06-11

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Scott Caroen ,  Tony R. Reid ,  Jeannie Williams

IPC: A61M1/34 ,  A61M1/36 ,  A61M1/38

CPC classification number: A61M1/342 ,  A61M1/3673 ,  A61M1/38 ,  A61M2202/0216 ,  A61M2202/0275 ,  A61M2205/3337 ,  A61M2205/7545

Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

公开(公告)号：US11999973B2

公开(公告)日：2024-06-04

申请号：US16604194

申请日：2018-04-10

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Christopher Larson

IPC: C12N7/00

CPC classification number: C12N7/00 ,  C12N2710/10321 ,  C12N2710/10322 ,  C12N2710/10332 ,  C12N2710/10352

Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

公开(公告)号：US11576895B2

公开(公告)日：2023-02-14

申请号：US16069012

申请日：2017-01-11

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Jan Scicinski ,  Scott Caroen

IPC: A61K31/397 ,  A61P35/02 ,  A61P35/00 ,  A61K9/00 ,  A61K31/194 ,  A61K31/727 ,  A61K35/14 ,  A61K47/10 ,  A61K47/18 ,  A61K47/46 ,  A61K9/08

Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.